NCT00421642已完成1 期
An Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Ulcerative Colitis Patients
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mayo Clinic
- 入组人数
- 20
- 试验地点
- 3
- 主要终点
- The Primary pilot efficacy variable will be the induction of clinical response, which is defined as a decrease in Mayo score less than 30% from baseline or less than 3 points PLUS decrease in rectal bleeding sub-score less than or equal to 1 at week 8
研究概览
简要总结
This is an open-label study of 20 patients designed to demonstrate the safety, tolerability and preliminary evidence of benefit of adalimumab in the treatment of subjects with Ulcerative Colitis, both in patients who have never received anit-TNF agents and in those who have lost response or developed intolerance to previous infliximab therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 18 years of age and older
- •Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).
- •A diagnosis of UC for greater than 3 months.
- •UC diagnosis confirmed by endoscopy with exclusion of infectious cause.
- •Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.
- •Either anti-TNF agent naïve or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.
- •Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.
- •Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.
排除标准
- •History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.
- •Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.
- •Subjects with Crohn?s Disease
- •Subjects with symptomatic obstructive strictures
- •Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.
- •Subjects who are currently receiving total parenteral nutrition (TPN).
- •Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated >/= 4 weeks from their last infliximab dose.
- •Antibiotic treatment for any systemic infection within 3 weeks prior to screening.
- •Female subjects who are pregnant or breast-feeding.
- •History of clinically significant drug or alcohol abuse in the prior year.
- •Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).
- •Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.
- •Subjects who have been on methotrexate within 4 weeks of screening.
结局指标
主要结局
The Primary pilot efficacy variable will be the induction of clinical response, which is defined as a decrease in Mayo score less than 30% from baseline or less than 3 points PLUS decrease in rectal bleeding sub-score less than or equal to 1 at week 8
时间窗: 24 Weeks
次要结局
- Clinical remission at each visit(24 Weeks)
- Clinical response at each visit(24 Weeks)
- Improvement in the mucosal inflammation at week 8(24 Weeks)
- Mayo Score(24 Weeks)
- Ability to taper and discontinue steroids according to the tapering schedule after week 8(24 Weeks)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806Crohn's DiseaseNCT00686374AbbVie (prior sponsor, Abbott)100
已完成
不适用
ltrasound Guided Synovial Biopsy to determine treatment response to Rituxumab versus TocilizumabTopic: MusculoskeletalSubtopic: Musculoskeletal (all Subtopics)Disease: Inflammatory ArthritisMusculoskeletal DiseasesRheumatoid arthritis, unspecifiedISRCTN97443826Queen Mary University of London (UK)164
招募中
1 期
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCMHypertrophic CardiomyopathyNCT05836259Tenaya Therapeutics30
招募中
1 期
A First-In-Human Trial of pTTL in Advanced Colorectal CancerColorectal CancerNCT05908643Neogap Therapeutics AB16
终止
2 期
The HAM Infliximab StudyHTLV-I-associated MyelopathyNCT00823641Imperial College London3